Clinical Trial

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2022 (before its estimated August 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T cells (fhB7H3.CAR-Ts) via using a '3+3+3' dose escalation design. In the dose expansion cohort, six patients will be enrolled to further assess their efficacy with the optimal dosage.
Trial Details
NCT Number NCT05211557
Lead Sponsor The Affiliated Hospital of Xuzhou Medical University
Collaborators: Xuzhou Medical University, IIT MediTech (Jiangsu) Co. Ltd
Conditions Ovarian Cancer
Enrollment 15 participants
Start Date 2021-11-16
Primary Completion 2023-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2022-01-27